-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News on May 13 A few days ago, the official website of the State Food and Drug Administration showed that simvastatin tablets from Sichuan Hairong Pharmaceutical of Yangtze River Pharmaceutical Group, simvastatin tablets from Shanghai Xinyi Wanxiang Pharmaceutical, and Xin from Hainan Hailing Chemical Pharmaceutical Vastatin tablets were approved on the same day as supplementary applications.
Meinenet data shows that in 2020, the total sales of simvastatin tablets at the terminals of Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 1 billion yuan.
Meinenet data shows that in 2020, the total sales of simvastatin tablets at the terminals of Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 1 billion yuan.
Data show that simvastatin tablets are hypolipidemic drugs, suitable for primary hypercholesterolemia, including heterozygous familial hypercholesterolemia, hyperlipidemia or mixed hyperlipidemia, homozygous familial hypercholesterolemia Children with hypercholesterolemia, coronary heart disease combined with hypercholesterolemia, and heterozygous familial hypercholesterolemia .
The original manufacturer of this product is Merck, and the domestic import was approved in 2000, and the license holder is Merck.
The original manufacturer of this product is Merck, and the domestic import was approved in 2000, and the license holder is Merck.
Source: One-click search on Mi Nei.
com
com
According to Meinenet data, in 2020, the total sales of simvastatin tablets in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (Chinese public medical institutions) and China's urban physical pharmacies will exceed 1 billion.
yuan.
Simvastatin tablets are highly competitive, with more than 70 manufacturers.
yuan.
Simvastatin tablets are highly competitive, with more than 70 manufacturers.
.
Source: MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
In terms of consistency evaluation, simvastatin tablets have been reviewed by 8 companies , of which 7 companies including Zhejiang Jingxin Pharmaceutical, Hisun Pfizer Pharmaceuticals, and Sichuan Hairong Pharmaceuticals of Yangtze River Pharmaceutical Group have been approved for supplementary applications.
Xiamen Lizhuo Pharmaceutical Co.
, Ltd.
has been approved for application for production of imitation 4 types, which is regarded as over-evaluated.
Xiamen Lizhuo Pharmaceutical Co.
, Ltd.
has been approved for application for production of imitation 4 types, which is regarded as over-evaluated.
Source: official website of the State Food and Drug Administration, Mi Nei.
com database
com database
Medical Network News on May 13 A few days ago, the official website of the State Food and Drug Administration showed that simvastatin tablets from Sichuan Hairong Pharmaceutical of Yangtze River Pharmaceutical Group, simvastatin tablets from Shanghai Xinyi Wanxiang Pharmaceutical, and Xin from Hainan Hailing Chemical Pharmaceutical Vastatin tablets were approved on the same day as supplementary applications.
Meinenet data shows that in 2020, the total sales of simvastatin tablets at the terminals of Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 1 billion yuan.
Meinenet data shows that in 2020, the total sales of simvastatin tablets at the terminals of Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 1 billion yuan.
Data show that simvastatin tablets are hypolipidemic drugs, suitable for primary hypercholesterolemia, including heterozygous familial hypercholesterolemia, hyperlipidemia or mixed hyperlipidemia, homozygous familial hypercholesterolemia Children with hypercholesterolemia, coronary heart disease combined with hypercholesterolemia, and heterozygous familial hypercholesterolemia .
The original manufacturer of this product is Merck, and the domestic import was approved in 2000, and the license holder is Merck.
The original manufacturer of this product is Merck, and the domestic import was approved in 2000, and the license holder is Merck.
Source: One-click search on Mi Nei.
com
com
According to Meinenet data, in 2020, the total sales of simvastatin tablets in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (Chinese public medical institutions) and China's urban physical pharmacies will exceed 1 billion.
yuan.
Simvastatin tablets are highly competitive, with more than 70 manufacturers.
yuan.
Simvastatin tablets are highly competitive, with more than 70 manufacturers.
.
Source: MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
In terms of consistency evaluation, simvastatin tablets have been reviewed by 8 companies , of which 7 companies including Zhejiang Jingxin Pharmaceutical, Hisun Pfizer Pharmaceuticals, and Sichuan Hairong Pharmaceuticals of Yangtze River Pharmaceutical Group have been approved for supplementary applications.
Xiamen Lizhuo Pharmaceutical Co.
, Ltd.
has been approved for application for production of imitation 4 types, which is regarded as over-evaluated.
Xiamen Lizhuo Pharmaceutical Co.
, Ltd.
has been approved for application for production of imitation 4 types, which is regarded as over-evaluated.
Source: official website of the State Food and Drug Administration, Mi Nei.
com database
com database
Medical Network News on May 13 A few days ago, the official website of the State Food and Drug Administration showed that simvastatin tablets from Sichuan Hairong Pharmaceutical of Yangtze River Pharmaceutical Group, simvastatin tablets from Shanghai Xinyi Wanxiang Pharmaceutical, and Xin from Hainan Hailing Chemical Pharmaceutical Vastatin tablets were approved on the same day as supplementary applications.
Meinenet data shows that in 2020, the total sales of simvastatin tablets at the terminals of Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 1 billion yuan.
Meinenet data shows that in 2020, the total sales of simvastatin tablets at the terminals of Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 1 billion yuan.
Data show that simvastatin tablets are hypolipidemic drugs, suitable for primary hypercholesterolemia, including heterozygous familial hypercholesterolemia, hyperlipidemia or mixed hyperlipidemia, homozygous familial hypercholesterolemia Children with hypercholesterolemia, coronary heart disease combined with hypercholesterolemia, and heterozygous familial hypercholesterolemia .
The original manufacturer of this product is Merck, and the domestic import was approved in 2000, and the license holder is Merck.
Child, child, kidThe original manufacturer of this product is Merck, and the domestic import was approved in 2000, and the license holder is Merck.
Source: One-click search on Mi Nei.
com
com
According to Meinenet data, in 2020, the total sales of simvastatin tablets in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (Chinese public medical institutions) and China's urban physical pharmacies will exceed 1 billion.
yuan.
Simvastatin tablets are highly competitive, with more than 70 manufacturers.
Hospital hospital hospital pharmacy pharmacy pharmacyyuan.
Simvastatin tablets are highly competitive, with more than 70 manufacturers.
.
Source: MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
In terms of consistency evaluation, simvastatin tablets have been reviewed by 8 companies , of which 7 companies including Zhejiang Jingxin Pharmaceutical, Hisun Pfizer Pharmaceuticals, and Sichuan Hairong Pharmaceuticals of Yangtze River Pharmaceutical Group have been approved for supplementary applications.
Xiamen Lizhuo Pharmaceutical Co.
, Ltd.
has been approved for application for production of imitation 4 types, which is regarded as over-evaluated.
Enterprise business enterpriseXiamen Lizhuo Pharmaceutical Co.
, Ltd.
has been approved for application for production of imitation 4 types, which is regarded as over-evaluated.
Source: official website of the State Food and Drug Administration, Mi Nei.
com database
com database
